clinical trial · NCT04678557
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
ViaCyte·phase2·terminated·n = 31
Type 1 DiabetesVC-01 Combination Product
brief summary
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.
started
Jun 25, 2019
primary completion
Nov 12, 2021
completion
Nov 19, 2021
last updated
Oct 18, 2023
detailed description
This trial will test if VC-01 combination product can be implanted and maintained with safety, tolerability, and efficacy for up to Month 12/Week 52.
official title
An Open-Label Phase 1/2 Study to Evaluate the Safety, Engraftment, and Efficacy of VC-01™Combination Product in Subjects With Type 1 Diabetes Mellitus [T1DM]
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol